CDT EQUITY INC (CDT) Fundamental Analysis & Valuation

NASDAQ:CDT • US20678X4034

Current stock price

5.89 USD
+0.77 (+15.04%)
At close:
6.3457 USD
+0.46 (+7.74%)
Pre-Market:

This CDT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CDT Profitability Analysis

1.1 Basic Checks

  • CDT had negative earnings in the past year.
  • CDT had a negative operating cash flow in the past year.
CDT Yearly Net Income VS EBIT VS OCF VS FCFCDT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • With a Return On Assets value of -242.03%, CDT is not doing good in the industry: 94.74% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -483.82%, CDT is doing worse than 91.23% of the companies in the same industry.
Industry RankSector Rank
ROA -242.03%
ROE -483.82%
ROIC N/A
ROA(3y)-32724%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDT Yearly ROA, ROE, ROICCDT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -20K -40K -60K -80K

1.3 Margins

  • CDT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDT Yearly Profit, Operating, Gross MarginsCDT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CDT Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for CDT has been reduced compared to 1 year ago.
  • Compared to 1 year ago, CDT has a worse debt to assets ratio.
CDT Yearly Shares OutstandingCDT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
CDT Yearly Total Debt VS Total AssetsCDT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

  • CDT has an Altman-Z score of -11.17. This is a bad value and indicates that CDT is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -11.17, CDT is not doing good in the industry: 92.98% of the companies in the same industry are doing better.
  • CDT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.17
ROIC/WACCN/A
WACCN/A
CDT Yearly LT Debt VS Equity VS FCFCDT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M -4M -6M -8M -10M

2.3 Liquidity

  • CDT has a Current Ratio of 1.66. This is a normal value and indicates that CDT is financially healthy and should not expect problems in meeting its short term obligations.
  • CDT has a Current ratio of 1.66. This is amonst the worse of the industry: CDT underperforms 80.70% of its industry peers.
  • CDT has a Quick Ratio of 1.66. This is a normal value and indicates that CDT is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of CDT (1.66) is worse than 61.40% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
CDT Yearly Current Assets VS Current LiabilitesCDT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. CDT Growth Analysis

3.1 Past

  • CDT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.17%, which is quite impressive.
EPS 1Y (TTM)71.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. CDT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CDT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDT Price Earnings VS Forward Price EarningsCDT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDT Per share dataCDT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5K -10K -15K -20K -25K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CDT Dividend Analysis

5.1 Amount

  • No dividends for CDT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CDT Fundamentals: All Metrics, Ratios and Statistics

CDT EQUITY INC

NASDAQ:CDT (4/9/2026, 8:16:41 PM)

Premarket: 6.3457 +0.46 (+7.74%)

5.89

+0.77 (+15.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-23
Earnings (Next)05-11
Inst Owners1.9%
Inst Owner Change0%
Ins Owners12.28%
Ins Owner Change0.1%
Market Cap26.03M
Revenue(TTM)N/A
Net Income(TTM)-20.70M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.09
P/tB 6.09
EV/EBITDA N/A
EPS(TTM)-26949.11
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-3.65
FCFYN/A
OCF(TTM)-3.33
OCFYN/A
SpS0
BVpS0.97
TBVpS0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -242.03%
ROE -483.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32724%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z -11.17
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.99%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-324.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-287.48%
OCF growth 3YN/A
OCF growth 5YN/A

CDT EQUITY INC / CDT Fundamental Analysis FAQ

What is the fundamental rating for CDT stock?

ChartMill assigns a fundamental rating of 1 / 10 to CDT.


Can you provide the valuation status for CDT EQUITY INC?

ChartMill assigns a valuation rating of 0 / 10 to CDT EQUITY INC (CDT). This can be considered as Overvalued.


Can you provide the profitability details for CDT EQUITY INC?

CDT EQUITY INC (CDT) has a profitability rating of 0 / 10.


Can you provide the financial health for CDT stock?

The financial health rating of CDT EQUITY INC (CDT) is 5 / 10.